Briacell Therap (NASDAQ:BCTX) Posts Quarterly Earnings Results

Briacell Therap (NASDAQ:BCTX) issued its quarterly earnings results on Wednesday. The company reported ($1.50) earnings per share (EPS) for the quarter, FiscalAI reports.

Briacell Therap Trading Down 1.7%

Shares of Briacell Therap stock opened at $3.50 on Thursday. The company’s fifty day simple moving average is $3.80 and its 200-day simple moving average is $3.89. The company has a market cap of $30.45 million, a price-to-earnings ratio of -0.44 and a beta of 1.21. Briacell Therap has a 1 year low of $2.60 and a 1 year high of $13.43.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Briacell Therap in a research report on Thursday, October 15th. One research analyst has rated the stock with a Sell rating. According to MarketBeat, the stock has a consensus rating of “Sell”.

Briacell Therap Company Profile

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. Its research is centered on treatments designed to stimulate a patient’s immune system to recognize and attack tumor cells, with an emphasis on advanced breast cancer and other solid tumors.

The company’s lead technology includes Bria-IMT, an off-the-shelf, whole-cell immunotherapy derived from a breast cancer cell line. BriaCell has also been developing Bria-OTS, a personalized immunotherapy approach intended to match treatment with a patient’s human leukocyte antigen profile.